Related Experiment Video
Updated: Dec 24, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Role of rat sarcoma virus mutations in cancer and potential target for cancer therapy
1ROSS University School of Medicine, Lloyd Erskine Sandiford Center, St Michael BB11039, Barbados.
Abstract:
The prevalence of oncogenic rat sarcoma virus (RAS) mutations has made RAS a popular target for cancer therapies. Significant discoveries have been reported regarding cancer molecular biology following the study of RAS mutations. These discoveries are integral in shaping the era of targeted cancer therapy, with direct targeting of RAS or downstream RAS effectors, such as Grb2 and MAPK a possibility. Novel agents such as farnesyltransferase directly bind and sequester RAS. While these new agents and approaches have shown promise in preclinical and clinical studies, the complexity of RAS signaling and the potential for robust adaptive feedback continue to present substantial challenges. Therefore, the development of targeted therapies will require a detailed understanding of the properties and dependencies of specific cancers to a RAS mutation. This review provides an overview of RAS mutations and their relationship with cancer and discusses their potential as therapeutic targets.
Insights
Oncogenic rat sarcoma virus (RAS) mutations are key drivers in cancer. Understanding RAS mutations and their complex signaling pathways is crucial for developing effective targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogenic rat sarcoma virus (RAS) mutations are prevalent in many cancers.
- RAS mutations significantly impact cancer molecular biology and signaling pathways.
- Targeting RAS and its downstream effectors represents a promising strategy in cancer therapy.
Purpose of the Study:
- To review the role of RAS mutations in cancer development.
- To discuss the potential of RAS and its effectors as therapeutic targets.
- To highlight the challenges in developing targeted RAS-based therapies.
Main Methods:
- Literature review of studies on RAS mutations in cancer.
- Analysis of RAS signaling pathways and their therapeutic implications.
- Evaluation of novel therapeutic agents targeting RAS.
Main Results:
- RAS mutations are central to cancer pathogenesis.
- Targeting RAS, Grb2, MAPK, and using agents like farnesyltransferase show therapeutic promise.
- Cancer cells exhibit complex adaptive feedback mechanisms in response to RAS-targeted therapies.
Conclusions:
- Targeted therapies require a deep understanding of specific cancer dependencies on RAS mutations.
- Further research into RAS signaling complexity is essential for advancing cancer treatment.
- RAS mutations remain a critical focus for developing next-generation cancer therapies.
More Related Videos
09:03Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model
Published on: October 16, 2017
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
The Ras Gene
Ras is a...
Mechanisms of Retrovirus-induced Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Cancer